M32.14 Glomerular disease in systemic lupus erythematosus

Name of the Condition

• Glomerular disease in systemic lupus erythematosus (ICD-10-CM: M32.14)

Summary

Glomerular disease in systemic lupus erythematosus (SLE) refers to kidney involvement where the immune system attacks the glomeruli, the filtering units of the kidneys. This condition is a common and serious manifestation of SLE, leading to inflammation and potential impairment of renal function. It is classified under the broader category of lupus nephritis, with specific focus on glomerular pathology.

Causes

The development of glomerular disease in SLE is driven by the underlying autoimmune process, where autoantibodies and immune complexes deposit in the glomeruli, triggering inflammation. Genetic predisposition, environmental triggers (e.g., infections, UV exposure), and hormonal factors may contribute to the onset and progression of this renal manifestation.

Risk Factors

• Pre-existing SLE with active disease
• Female gender (higher prevalence in women)
• Ethnicity (higher incidence in African Americans, Hispanics, Asians)
• Family history of autoimmune diseases
• Prolonged or uncontrolled SLE activity
• Exposure to certain medications or infections

Symptoms

• Proteinuria (excess protein in urine)
• Hematuria (blood in urine)
• Edema (swelling, especially in legs or face)
• Hypertension (high blood pressure)
• Reduced urine output
• Fatigue or malaise
• Nausea or vomiting (in advanced cases)

Diagnosis

Diagnosis involves a combination of clinical evaluation, laboratory tests, and imaging. Urinalysis and urine protein quantification assess kidney function, while blood tests measure creatinine, blood urea nitrogen (BUN), and autoantibodies (e.g., anti-dsDNA). A kidney biopsy may be performed to confirm glomerular involvement and determine the severity of lupus nephritis.

Treatment Options

Treatment focuses on controlling inflammation and preserving renal function. Corticosteroids and immunosuppressants (e.g., mycophenolate, cyclophosphamide) are commonly used. Blood pressure management, including ACE inhibitors or ARBs, helps reduce proteinuria. In severe cases, dialysis or kidney transplantation may be necessary.

Prognosis and Follow-Up

Prognosis varies based on the severity of glomerular damage and response to treatment. Early diagnosis and aggressive management improve outcomes. Regular monitoring of kidney function, blood pressure, and disease activity is essential. Long-term follow-up with a nephrologist and rheumatologist is recommended to prevent progression and manage complications.

Complications

• Chronic kidney disease (CKD) or end-stage renal disease (ESRD)
• Hypertension
• Nephrotic syndrome
• Increased risk of infections due to immunosuppressive therapy
• Cardiovascular disease

Lifestyle & Prevention

• Maintain a low-sodium, kidney-friendly diet
• Monitor and control blood pressure
• Avoid smoking and limit alcohol
• Protect skin from UV exposure
• Stay up-to-date with vaccinations (e.g., flu, pneumonia)
• Manage stress and prioritize rest

When to Seek Professional Help

Seek immediate medical attention if you experience severe symptoms such as sudden swelling, chest pain, difficulty breathing, or reduced urine output. Regular follow-up is critical for monitoring disease activity and adjusting treatment.

Tips for Medical Coders

Document the presence of glomerular disease in SLE clearly in the medical record, including clinical findings (e.g., proteinuria, hematuria) and diagnostic results (e.g., biopsy). Ensure the code M32.14 is used when glomerular involvement is specified, and avoid using this code if the documentation is unclear or refers to non-glomerular renal manifestations.